Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 2016

TUSTIN, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company committed to improving patient lives by delivering high quality biological products through its contract development and manufacturing organization (CDMO) services and by advancing its novel R&D pipeline, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2016 on July 14, 2016 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the quarter and FY ended April 30, 2016 and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products.  Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers.  The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers.  For more information, please visit www.peregrineinc.com.

Contacts:
Jay Carlson    
Peregrine Pharmaceuticals, Inc.
(800) 987-8256    
[email protected]  

Stephanie Diaz (Investors) 
Vida Strategic Partners  
415-675-7401   
[email protected]  

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
[email protected]

Source: Peregrine Pharmaceuticals Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• St. Joe Company (JOE) Reports Q1 EPS of $0.24
• Core Laboratories (CLB) Misses Q1 EPS by 13c
• First Internet Bancorp (INBK) Tops Q1 EPS by 5c